
Sleep & appetite
Why Sleep Belongs in the Conversation About Appetite and Weight
How sleep relates to appetite, what the research does and does not show, and when to bring sleep concerns to a clinician.
A little clarity goes a long way
Clear answers about medicines, food, and metabolic health—so you can understand the evidence and ask the questions that matter to you.
Free to explore. Grounded in sources. Made for real life.

Before your first GLP-1
A good place to start
5 min read · Practical guide
Understand the options and the science behind them.
Prepare questions about treatment, side effects, and care.
Explore appetite, nutrition, weight changes, and metabolism.
The reading room
Thoughtful guides for the questions behind the headlines.

Sleep & appetite
How sleep relates to appetite, what the research does and does not show, and when to bring sleep concerns to a clinician.

BMI, in context
Understand what BMI measures, why it is used, and which questions help put the number in context.

Choosing telehealth care
How to assess a telehealth service’s clinician, pharmacy, medicine, total cost, and ongoing care before signing up.
Stay curious
What’s new, what it means, and what’s still uncertain.
National Institutes of Health · Human observations + animal research
NIH reports that researchers linked blood-pressure medicines called ARBs with greater brown-fat activity in medical records from more than 100,000 people who underwent cancer imaging. Follow-up experiments found that losartan increased brown-fat activity in cells and mice. The treated mice maintained a steady body weight.
Read the contextAmerican Diabetes Association · Survey findings
An American Diabetes Association survey highlights the financial pressure of diabetes and obesity care. Nearly one in four surveyed households reported spending at least $200 a month on obesity medicines. The online survey gathered responses in June and July 2026 from ADA advocates and market-research panel participants.
Read the contextUS Food and Drug Administration · FDA safety communication
In January 2026, FDA requested removal of the suicidal-thoughts-and-behavior warning from Saxenda, Wegovy, and Zepbound labeling after its review found no increased risk associated with GLP-1 medicines. Its analysis included 91 placebo-controlled trials with 107,910 participants, alongside other evidence.
Read the contextA little understanding goes a long way
Build an appointment question list, explore the medicine names or try a short lesson. Free tools to help you take your next step.
Explore tools & activities →Start with your question
Choose a starting point, then follow a few clear steps at your own pace.
Find my starting point →WeightLiteracy is a project of Healthy Weight Literacy Foundation. We make health information easier to understand, with free education, clear sources, and respect for the person behind every question.